Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

44%

4 trials in Phase 3/4

Results Transparency

100%

7 of 7 completed trials have results

Key Signals

7 with results

Enrollment Performance

Analytics

Phase 3

4(80.0%)

Phase 2

1(20.0%)

5Total

Phase 3(4)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT05421806Active Not Recruiting

A Cohort Study of Use of Doravirine (DOR) Based Regimens in Clinical Practice in Europe DoRavirine Europe Real World/

Role: lead

NCT03696160Phase 3Completed

The Late Presenter Treatment Optimisation Study

Role: lead

NCT02344290Phase 3Completed

Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults

Role: collaborator

NCT05965427Completed

Morbidity, Mortality And Risk Factors of Mpox in HIV Negative High Risk Sexual Health Clinic Attenders and People Living With HIV

Role: lead

NCT05593770Phase 2Terminated

International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response

Role: lead

NCT05481216Completed

HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV

Role: lead

NCT05349838Phase 3Completed

Open-Label Multi-Centre Randomised Switch Study to Evaluate Virological Efficacy Over 96Weeks Of 2-Drug Therapy With Dolutegravir(DTG)/Rilpivirine(RPV) Fixed Dose Combination(FDC) in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With NNRTI Mutation K103N

Role: lead

NCT04847622Completed

Study to Evaluate the Clinical Outcomes in Adults With Covid-19 Who Have Been Treated With Remdesivir.

Role: lead

NCT04373733Phase 3Completed

Early Intervention in COVID-19: Favipiravir Verses Standard Care

Role: collaborator

All 9 trials loaded